Chris is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization.
Chris joined Frazier in May 2017 as founder of Flashlight Therapeutics, a search company focused on identifying and in-licensing assets to treat liver diseases, cancers, and related diseases. He is also the CEO of Mirum Pharmaceuticals, a Frazier portfolio company.
Chris previously served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics for non-alcoholic steatohepatitis. While at Tobira, Chris led the company's efforts to become a public company, expand its pipeline through partnership and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix.
Chris holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.
Washington University (B.S.B.A)
Stanford University (M.B.A.)